Should the blood pressure target for all individuals with type 2 diabetes and hypertension be <130/80 mmHg? Should metformin be considered first-line therapy for individuals with type 2 diabetes with established arteriosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD? An expert panel that includes Paul K. Whelton, MB, MD, MSc, will tackle these clinical questions during a two-hour Current Issues debate beginning at 4:30 p.m. CT.
Coming up: Experts will debate recommendations for blood pressure targets, metformin use
